Data −Jul 13, 2026
Negative data — Disappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2▸
high impact
EarningsJul 06, 2026
Q1 2026 report+2.8%muted
DealJun 28, 2026
Deal — RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why▸
medium impact
FilingMay 31, 2026
Regulatory filing — Regeneron (REGN) Says EMA Accepted Review for Otarmeni Application▸
medium impact
Data −May 26, 2026
Negative data — Canaccord Cuts PT on Regeneron Pharmaceuticals (REGN), Cites a Disappointing Event▸
high impact
FilingMay 22, 2026
Regulatory filing — Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss▸
medium impact
Data −May 20, 2026
Negative data — Why Regeneron (REGN) Shares Are Trading Lower Today▸
high impact
Data +May 19, 2026
Positive data — Why Regeneron Pharmaceuticals (REGN) Is Down 11.7% After Key Melanoma Combo Trial Missed Its Goal▸
high impact
Data −May 19, 2026
Negative data — A Look At Regeneron Pharmaceuticals (REGN) Valuation After Melanoma Trial Setback And Share Price Pullback▸
high impact
Data −May 18, 2026
Negative data — Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.▸
high impact
ApprovalMay 09, 2026
FDA approval — Regeneron’s Otarmeni Win Links Gene Therapy Ambition With ESG Commitments▸
high impact
EarningsApr 29, 2026
Q1 2026 report+3.3%positive
EarningsApr 08, 2026
Q1 2026 report-3.7%negative
EarningsJan 30, 2026
FY 2025 report+4.5%positive
EarningsJan 12, 2026
FY 2025 report-3.4%negative
EarningsOct 28, 2025
Q3 2025 report-0.4%muted
EarningsOct 06, 2025
Q3 2025 report-2.7%muted
EarningsAug 01, 2025
Q2 2025 report-0.7%muted
EarningsApr 29, 2025
Q1 2025 report+6.5%positive
EarningsFeb 04, 2025
FY 2024 report+1.9%muted
EarningsJan 13, 2025
FY 2024 report-3.3%negative
EarningsOct 31, 2024
Q3 2024 report-1.0%muted
EarningsOct 07, 2024
Q3 2024 report+0.3%muted
EarningsAug 01, 2024
Q2 2024 report-2.5%muted